Abstract：
Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor that can be sporadic or inherited and is often associated with mutations in the RET (Rearranged during Transfection) oncogene. The primary treatment for MTC is surgical resection of all suspected disease, but recent advances in targeted therapies for MTC, including the selective RET inhibitors selpercatinib and pralsetinib, have led to changes in the management of patients with locally advanced, metastatic, or recurrent MTC. In this article, we review updates on the evaluation and management of patients with MTC, focusing on new and emerging therapies that are likely to improve patient outcomes.
摘要：
甲状腺髓样癌（MTC）是一种罕见的神经内分泌肿瘤，可以是散发性或遗传性的，通常与RET（转染过程中重排）癌基因的突变有关。MTC的主要治疗方法是手术切除所有可疑疾病，但是MTC靶向治疗的最新进展，包括选择性RET抑制剂selpercatinib和pralsetinib，导致了局部晚期患者管理的变化，转移性，或复发性MTC。在这篇文章中,我们回顾了MTC患者评估和管理的最新情况，专注于可能改善患者预后的新兴疗法。
